These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 23565455)
1. Baseline results indicate poor glycemic control and delay in initiation and optimization of insulin therapy: results from the improving management practices and clinical outcomes in type 2 diabetes study. Moses CR; Seshiah V; Sahay BK; Kumar A; Asirvatham AJ; Balaji V; Kalra S; Akhtar S; Shetty R; Das AK Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S432-3. PubMed ID: 23565455 [TBL] [Abstract][Full Text] [Related]
2. Physicians' perceptions of a national consensus guideline on insulin therapy: Data from the IMPACT study. Kalra S; Moses CR; Seshiah V; Sahay BK; Kumar A; Asirvatham AJ; Balaji V; Das AK; Akhtar S; Shetty R Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S426-7. PubMed ID: 23565452 [TBL] [Abstract][Full Text] [Related]
3. Improving management practices and clinical outcomes in type 2 diabetes study: Prevalence of complications in people with type 2 diabetes in India. Das AK; Seshiah V; Sahay BK; Kumar A; Asirvatham AJ; Balaji V; Kalra S; Channabasavaiah R; Shetty R; Moses CR Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S430-1. PubMed ID: 23565454 [TBL] [Abstract][Full Text] [Related]
4. Physician perceptions and practices in management of diabetes in India: Results from the IMPROVE Control program. Unnikrishnan AG; Wangnoo SK; Joshi SR; Banerjee S; Kumar A; Kalra S; Channabasavaiah R; Shetty R Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S428-9. PubMed ID: 23565453 [TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics of the IMPROVE control study population: A study to evaluate the effectiveness of a standardized healthcare professionals training program. Sharma SK; Seshiah V; Sahay BK; Das AK; Rao PV; Shah S; Akhtar S; Shetty R Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S471-3. PubMed ID: 23565470 [TBL] [Abstract][Full Text] [Related]
6. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Vinik A Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925 [TBL] [Abstract][Full Text] [Related]
7. Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study. Bu S; Zhang X; Zhu H; Shuai Y; Xing X; Yang W; Diabetes Ther; 2017 Aug; 8(4):887-898. PubMed ID: 28623551 [TBL] [Abstract][Full Text] [Related]
8. A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes. Miyoshi H; Baxter M; Kimura T; Hattori M; Morimoto Y; Marinkovich D; Tamiwa M; Hirose T Diabetes Ther; 2021 May; 12(5):1341-1357. PubMed ID: 33730337 [TBL] [Abstract][Full Text] [Related]
9. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500 [TBL] [Abstract][Full Text] [Related]
10. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study. Jin Y; Sun X; Zhao X; Zhu T Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442 [TBL] [Abstract][Full Text] [Related]
11. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775 [TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study. Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483 [TBL] [Abstract][Full Text] [Related]
13. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898 [TBL] [Abstract][Full Text] [Related]
14. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Ilag LL; Kerr L; Malone JK; Tan MH Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926 [TBL] [Abstract][Full Text] [Related]
15. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Kostev K; Dippel FW; Rathmann W Diabetes Metab Syndr Obes; 2015; 8():45-8. PubMed ID: 25609990 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes. Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482 [TBL] [Abstract][Full Text] [Related]
17. Best Practices and Tools for Titrating Basal Insulins: Expert Opinion from an Indian Panel via the Modified Delphi Consensus Method. Jain SM; Seshadri K; Unnikrishnan AG; Chawla M; Kalra P; Vipin VP; Ravishankar E; Chordia J; Das S; Wasir J; Bandookwala SM; Deka N; Agarwal G; Vijaykumar G; Erande S Diabetes Ther; 2020 Mar; 11(3):621-632. PubMed ID: 32009224 [TBL] [Abstract][Full Text] [Related]
18. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Davies M; Evans R; Storms F; Gomis R; Khunti K Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063 [TBL] [Abstract][Full Text] [Related]
19. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V; Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]